Advances in systemic therapy for metastatic breast cancer: future perspectives

Breast cancer (BC) is the most common cancer in women worldwide. One in eight women will develop the disease in her lifetime. Notwithstanding the incredible progress made in this field, BC still represents the second most common cause of cancer-related death in women. Targeted drugs have revolutioni...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2017-07, Vol.34 (7), p.119-119, Article 119
Main Authors: Corona, S. P., Sobhani, N., Ianza, A., Roviello, G., Mustacchi, G., Bortul, M., Zanconati, F., Generali, D.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Estrogen Receptor alpha - genetics
Female
Hematology
High-Throughput Nucleotide Sequencing
Humans
Immunotherapy - methods
Internal Medicine
Medicine
Medicine & Public Health
Molecular Targeted Therapy - methods
Mutation
Oncology
Pathology
Receptor, ErbB-2 - metabolism
Receptors, Progesterone - metabolism
Review Article
Triple Negative Breast Neoplasms - pathology
Triple Negative Breast Neoplasms - therapy
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer (BC) is the most common cancer in women worldwide. One in eight women will develop the disease in her lifetime. Notwithstanding the incredible progress made in this field, BC still represents the second most common cause of cancer-related death in women. Targeted drugs have revolutionised breast cancer treatment and improved the prognosis as well as the life expectancy of millions of women. However, the phenomenon of primary and secondary pharmacological resistance is becoming increasingly evident, limiting the efficacy of these agents and calling for a better in-depth knowledge and understanding of the biology as well as the biochemical crosstalk underlying the disease. The advent of laboratory technologies in the clinical setting such as the routine use of next generation sequencing has allowed identification of new genetic alterations as well as providing a precise picture of the molecular landscapes of each tumour. Consequently, new specific therapeutic approaches are becoming available to minimise or delay the occurrence of resistance. In this review, we analyse the latest research and news from the clinical development side for each BC subtype.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-017-0975-5